by Saroj Niraula
The Breast: February 2019, Volume 43, Pages 81-84
Three Cyclin Dependent
Kinase 4/6 (CDK) inhibitors have been approved by the United Stated Food and
Drug Administration for front line treatment of advanced hormone receptor
positive breast cancer based on improvements in progression free survival
against endocrine monotherapy. Two clinical trials have so far reported results
on overall survival but both are negative. CDK inhibitors are usually tolerated
well but they do add to inconvenience and cost - for example, grade III-IV
neutropenia occur at a frequency of over 60% requiring frequent blood work at
least during the initial months of treatment.
